Literature DB >> 22998552

Vibration thresholds are increased at low frequencies in the sole of the foot in diabetes-a novel multi-frequency approach.

J Nelander1, T Speidel, A Björkman, L B Dahlin.   

Abstract

AIMS: To evaluate multi-frequency tactilometry as a method to measure vibrotactile sense in the sole of the foot in subjects with diabetes.
METHODS: Vibration thresholds were investigated at five frequencies (8, 16, 32, 64 and 125 Hz) at three sites (first and fifth metatarsal heads and heel) in the sole of the foot in subjects with Type 1 and Type 2 diabetes (n = 37). Thresholds were compared with healthy, age- and gender-matched subjects (n = 37) and related to glycaemic levels, subjective estimation of sensation in the feet and to perception of touch.
RESULTS: Vibration thresholds were significantly higher in subjects with diabetes compared with healthy subjects at low frequencies (8, 16 and 32 Hz) at all measured sites, and also at 64 Hz for the metatarsal heads. Perception of touch and subjective estimation of sensation were significantly impaired in subjects with diabetes. Glycaemic levels, which were higher in subjects with diabetes, did not correlate with vibration thresholds at 32 Hz (most sensitive to Meissner's corpuscles) or with touch thresholds in subjects with diabetes. Vibration thresholds at 32 Hz correlated significantly with perception of touch (rho = 0.45-0.65; P < 0.01) and with subjective sensation (rho = -0.38 to -0.52; P < 0.001) in subjects with diabetes. Perception of touch and subjective estimation of sensation did also correlate (rho = -0.51 to -0.80; P < 0.002).
CONCLUSIONS: Tactilometry is effective in detecting neuropathy in the sole of the foot at low frequencies of mainly 8-32 Hz, indicating that at least Meissner's corpuscles, or their related large nerve fibres, are affected by diabetes.
© 2012 The Authors. Diabetic Medicine © 2012 Diabetes UK.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22998552     DOI: 10.1111/dme.12024

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  7 in total

1.  Vibrotactile perception in finger pulps and in the sole of the foot in healthy subjects among children or adolescents.

Authors:  Lars B Dahlin; Nuray Güner; Helena Elding Larsson; Toni Speidel
Journal:  PLoS One       Date:  2015-04-02       Impact factor: 3.240

2.  Impaired vibrotactile sense in children and adolescents with type 1 diabetes - Signs of peripheral neuropathy.

Authors:  Erik Ising; Lars B Dahlin; Helena Elding Larsson
Journal:  PLoS One       Date:  2018-04-19       Impact factor: 3.240

3.  Strong association between vibration perception thresholds at low frequencies (4 and 8 Hz), neuropathic symptoms and diabetic foot ulcers.

Authors:  Eero Lindholm; Magnus Löndahl; Katarina Fagher; Jan Apelqvist; Lars B Dahlin
Journal:  PLoS One       Date:  2019-02-28       Impact factor: 3.240

4.  Vibrotactile perception on the sole of the foot in an older group of people with normal glucose tolerance and type 2 diabetes.

Authors:  Magnus Peterson; Ronnie Pingel; Olov Rolandsson; Lars B Dahlin
Journal:  SAGE Open Med       Date:  2020-06-13

5.  Improved metabolic control using glucose monitoring systems leads to improvement in vibration perception thresholds in type 1 diabetes patients.

Authors:  Lars B Dahlin; Targ Elgzyri; Magnus Löndahl; Linnéa Ekman; Eero Lindholm
Journal:  Acta Diabetol       Date:  2019-11-08       Impact factor: 4.280

6.  Addressing Chemotherapy-Induced Peripheral Neuropathy Using Multi-Frequency Vibrometry and Patient-Reported Outcomes.

Authors:  Sebastian W Nielsen; Sanne Lindberg; Christina Halgaard Bruvik Ruhlmann; Lise Eckhoff; Jørn Herrstedt
Journal:  J Clin Med       Date:  2022-03-27       Impact factor: 4.241

7.  Gender differences in nerve regeneration after sciatic nerve injury and repair in healthy and in type 2 diabetic Goto-Kakizaki rats.

Authors:  Lena Stenberg; Lars B Dahlin
Journal:  BMC Neurosci       Date:  2014-09-13       Impact factor: 3.288

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.